Exelixis Faces Setback as FDA Extends Review of Zanzalintinib
Exelixis faces uncertainty as the FDA prolongs its review of zanzalintinib, raising questions about future revenue and stock performance.
SPS Commerce Stock Jumps Amid Acquisition Talks with GTCR
SPS Commerce shares surged as GTCR expresses acquisition interest. Explore the implications for the tech sector.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
NextEra and Dominion Merger: A New Era for U.S. Utilities
The merger between NextEra Energy and Dominion Energy could reshape the U.S. utility landscape, impacting customers and …
Merck and Moderna's mRNA Breakthrough: Implications for the Future of Cancer Treatment
The Phase 3 INTerpath-001 trial results present significant implications for Merck and Moderna's cancer treatment strate…
Quantum BioPharma's FDA Clearance: A Game Changer for MS Treatment
Quantum BioPharma's FDA clearance for Lucid-MS could reshape MS treatment and enhance investor confidence.
Technical Analysis: US Stocks at a Crossroads Amid Rising Oil Prices and Inflation Concerns
As rising oil prices and inflation loom, US stocks face critical support levels that could shape market sentiment.
Merck (MRK) and Moderna (MRNA) Achieve Breakthrough in mRNA Cancer Vaccine Development: What it Means for Investors
Merck and Moderna's Phase 3 trial results for their mRNA cancer vaccine could reshape oncology and investor sentiment.
Revolution Medicines (RVMD) Gains Momentum Post-FDA Approval: What Investors Should Know
Revolution Medicines is gaining traction following FDA approval for Rasonque, signaling potential market shifts.
Revolution Medicines Gains Traction with FDA Approval of Rasonque and Morgan Stanley Overweight Rating
Revolution Medicines sees renewed investor interest as Rasonque gains FDA approval and Morgan Stanley issues an Overweig…
Genentech's Enspryng Gets FDA Priority Review for MOGAD: What the Accelerated Timeline Means
The FDA's Priority Review of Enspryng for rare disease MOGAD could compress Genentech's approval timeline and unlock a n…
Axogen Expands Nerve Repair Portfolio with $200M BioCircuit Acquisition
Axogen's $200M acquisition of BioCircuit Technologies marks a significant expansion in the nerve repair market.